Top-Rated StocksTop-RatedNASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis $13.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.64 -0.41 (-3.16%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunic Stock (NASDAQ:IMUX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunic alerts:Sign Up Key Stats Today's Range$12.48▼$13.8050-Day Range$8.80▼$13.6552-Week Range$5.06▼$15.10Volume326,555 shsAverage Volume288,888 shsMarket Capitalization$177.74 millionP/E RatioN/ADividend YieldN/APrice Target$47.57Consensus RatingBuy Company Overview Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients. Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis. A second program, IMU-935, targets the RORγt pathway, with preclinical and early-stage clinical studies designed to assess its potential in treating psoriasis and other inflammatory disorders. Both programs reflect the company’s commitment to advancing therapies that may offer improved efficacy and convenience compared to existing injections or infusions. Founded in 2008 and headquartered in New York, Immunic maintains research operations in Germany to leverage its European expertise in medicinal chemistry and translational science. This transatlantic footprint supports robust clinical trial activity and enables collaboration with international academic and clinical partners. Over the years, the company has progressed its pipeline through strategic financing rounds and regulatory engagement, culminating in its NASDAQ listing in early 2020. Under the leadership of Chief Executive Officer Friederike Bertram, M.D., Immunic continues to expand its pipeline and explore additional indications for its platform of oral immunology agents. Guided by a management team experienced in drug development and regulatory affairs, the company aims to bring new therapeutic options to patients living with immune-mediated diseases and certain oncologic conditions.AI Generated. May Contain Errors. Read More Immunic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreIMUX MarketRank™: Immunic scored higher than 76% of companies evaluated by MarketBeat, and ranked 159th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialImmunic has a consensus price target of $47.57, representing about 264.5% upside from its current price of $13.05.Amount of Analyst CoverageImmunic has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($4.28) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immunic's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.41% of the float of Immunic has been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immunic has recently decreased by 83.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.52 News SentimentImmunic has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Immunic this week, compared to 4 articles on an average week.Search Interest29 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat Follows10 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by Insiders14.00% of the stock of Immunic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunic's insider trading history. Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMUX Stock News HeadlinesImmunic (NASDAQ:IMUX) Price Target Cut to $27.00 by Analysts at B. Riley FinancialMay 23 at 3:40 AM | americanbankingnews.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 25 at 1:00 AM | Brownstone Research (Ad)Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Immunic (IMUX)May 19, 2026 | theglobeandmail.comImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of DirectorsMay 19, 2026 | prnewswire.comImmunic (IMUX) Gets a Buy from LifeSci CapitalMay 18, 2026 | theglobeandmail.comImmunic Q2 EPS Estimate Boosted by Brookline Capital MarketsMay 18, 2026 | americanbankingnews.comIs Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?May 17, 2026 | finance.yahoo.comSee More Headlines IMUX Stock Analysis - Frequently Asked Questions How have IMUX shares performed this year? Immunic's stock was trading at $5.3370 at the start of the year. Since then, IMUX stock has increased by 144.5% and is now trading at $13.05. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.37. When did Immunic's stock split? Shares of Immunic reverse split on Monday, April 27th 2026.The 1-10 reverse split was announced on Thursday, April 23rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Immunic IPO? Immunic (IMUX) raised $63 million in an initial public offering on Thursday, April 17th 2014. The company issued 4,500,000 shares at a price of $13.00-$15.00 per share. Who are Immunic's major shareholders? Top institutional shareholders of Immunic include Renaissance Technologies LLC (6.75%), Simplify Asset Management Inc. (0.32%), OMERS ADMINISTRATION Corp (1.24%) and Bank of America Corp DE (1.06%). Insiders that own company stock include Richard Alan Rudick, Duane Nash and Daniel Vitt. View institutional ownership trends. How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings5/13/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 4 weeks, IMUX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMUX CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees70Year Founded2003Price Target and Rating Average Price Target for Immunic$47.57 High Price Target$130.00 Low Price Target$19.00 Potential Upside/Downside+264.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($5.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-220.75% Return on Assets-132.04% Debt Debt-to-Equity RatioN/A Current Ratio4.92 Quick Ratio4.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.10 per share Price / Book1.18Miscellaneous Outstanding Shares13,620,000Free Float11,715,000Market Cap$177.74 million OptionableOptionable Beta1.20 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:IMUX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
